Evommune, Inc. Raises $12.5M in Seed Funding to Accelerate the Development of Transformative Medicines for Chronic Inflammatory Diseases – PRNewswire

LOS ALTOS, Calif., Nov. 18, 2020 /PRNewswire/ --Evommune, Inc., an innovation engine inchronic inflammation, announced the successful completion of a $12.5million seed financing by Pivotal bioVenture Partners. This financing will enable Evommune to build a pipeline of unique therapies for patients with chronic inflammatory diseases.

Approximately 60 percent of Americans live with chronic inflammatory diseases, and it is expected that the prevalence will increase steadily over the next 30 years.1 Evommune wants to improve the quality of life for patients living with these conditions. The company is using the skin as the lens to uncover new approaches for accelerating the development of vital medicines across immunology with a focus on inflammation and dermatology. By utilizing a novel screening platform, the company will identify molecules that are differentiated and have a greater probability of being effective in treating patients with chronic inflammatory conditions.

"There has been tremendous progress in the treatment of inflammatory diseases, but there are still many conditions that lack safe and effective therapies. This is where Evommune will make a difference," said Luis Pea, president and chief executive officer, Evommune, Inc. "This initial seed funding will be used to set up and drive the execution of our longer-term strategy. We have established both academic and industry collaborations and are building a pipeline that will include both discovery and clinical-stage development programs."

Evommune was co-founded by industry veterans Luis Pea, Eugene A. Bauer, MD, chief medical officer, and Hans Hofland, PhD, senior vice president, research. In addition to the founders Janice Drew, MPH joins the executive team as senior vice president, product development. All of the executives were former senior leaders at Dermira, Inc. which was subsequently sold to Eli Lilly and Company for approximately $1.1 billion in 2020. Together, the team is highly accomplished in global drug development and has an outstanding 30-year track record of rapid regulatory approvals and successful development of medicines across multiple therapeutic areas, including immunology and dermatology.

"We are always looking to invest in talented and passionate founders who are on a mission to develop new and innovative therapeutics," said Rob Hopfner, RPh, PhD, MBA, managing partner at Pivotal bioVenture Partners. "The Evommune team's years of immunology and dermatology experience gives them an edge in identifying and developing therapies that will improve the lives of patients with debilitating diseases."

Ash Khanna, PhD, MBA, venture partner at Pivotal bioVenture Partners noted, "There is a great need for new solutions to address chronic inflammation and we are delighted to partner with the stellar Evommune team for Pivotal's first seed-stage investment."

About Evommune, Inc. Evommune is a private, R&D company and innovation engine in chronicinflammation. Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases. The company is headquartered in Los Altos, California. For more information please visit Evommune.com.

About Pivotal bioVenture PartnersPivotal bioVenture Partners is a $300 million life sciences venture capital fund located in San Francisco, California. The fund invests in privately held companies developing innovative therapeutic products and platforms to address major unmet medical needs. Investments range from seed-stage deals to cross-over financings at all stages of the preclinical and clinical development spectrum.Pivotal's investment team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses. For more information please visit https://pivotalbiovp.com

1 Pahwa R, Goyal A, Bansal P, et al. Chronic Inflammation. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/

Media Contact:Sheryl Seapy 949-903-4750[emailprotected]

SOURCE Evommune, Inc.

Read the rest here:
Evommune, Inc. Raises $12.5M in Seed Funding to Accelerate the Development of Transformative Medicines for Chronic Inflammatory Diseases - PRNewswire

University of Miami Health System Gastroenterologist Honored with Lifetime Disruptor Award – Newswise

Newswise Maria T. Abreu, M.D., a renowned gastroenterologist at the University of Miami Miller School of Medicine, was honored with the Lifetime Disruptor award at the American College of Gastroenterologys 2020 virtual meeting. Healio, an in-depth specialty clinical information service, presented the award, which was based on votes from her peers.

I am always challenging the accepted wisdom, said Dr. Abreu, who is professor of medicine and microbiology and immunology, and director of the University of Miami Health System Crohns & Colitis Center. There is always more to learn about a certain condition or treatment to see if we can do something more to help our patients.

A leader in basic science, translational research, clinical care and education, Dr. Abreu focuses her work on finding better treatments for inflammatory bowel disease (IBD) and other debilitating gastrointestinal conditions. She is also a leader in bringing the genetic and environmental factors of IBD development in the Hispanic population into research and clinical care.

In my laboratory work, I look for new approaches to improving patient care, such as reducing an inflammatory response from the immune system or providing a healthy diet to reduce IBD flare-ups, she said.

The Healio Lifetime Disruptor award, presented this year on Oct. 26, goes to a gastroenterologist or hepatologist who has consistently pushed the gastroenterology field forward through innovative treatments, practice management, patient care, or research. This year more than 1,000 readers and followers voted on eight awards for Healio Disruptive Innovators.

In 2019 Dr. Abreu received the Sherman prize awarded by The Bruce and Cynthia Sherman Charitable Foundation to recognize outstanding achievements in the fight to overcome Crohn's disease and ulcerative colitis. Taking care of patients and finding new ways to help them has been my lifes purpose, she said at the time. Thats what inspires my research the possibility of helping both my patients, as well as those that Ill never see.

Earlier this year, Dr. Abreu was honored with the Research Mentor Award by the American Gastroenterological Association(AGA) Institute CouncilsImmunology, Microbiology & Inflammatory Bowel Diseases Section. It is so important to be educating and mentoring young professionals and help them move ahead with their careers, Dr. Abreu said. They are the future of medicine.

Here is the original post:
University of Miami Health System Gastroenterologist Honored with Lifetime Disruptor Award - Newswise

Study reveals the metabolic signaling mechanisms that regulate function of eTreg cells – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Nov 17 2020

Effector regulatory T cells (eTreg cells) are a specialized subset of white blood cells that keep the immune system in check. St. Jude Children's Research Hospital scientists have revealed the metabolic signaling mechanisms that regulate function of eTreg cells. The work may aid efforts to better understand and treat inflammatory diseases. The findings were published online today in Cell Metabolism.

This process is quite fascinating to us, and helps explain how metabolites can drive selective signaling pathways to enforce the differentiation, persistence and function of eTreg cells. We were looking specifically at suppression of autoimmunity that can develop spontaneously in our models, but we also know Treg cells play a role in multiple diseases."

Hongbo Chi, Ph.D., Corresponding Author, St. Jude Immunology

Although eTreg cells are involved in prevention of autoimmune diseases, including lupus and rheumatoid arthritis, they are detrimental in other diseases, such as cancer. Understanding how metabolic signaling regulates Treg cell heterogeneity or function may help scientists develop more specific drugs to target these pathways to help treat disease. How metabolic pathways regulate the differentiation and persistence of eTreg cells, especially at the level of intracellular signaling, has been unclear until now.

The researchers showed that two-way metabolic signaling that intersects with T cell receptor signaling is critical to regulating eTreg cell function.

Investigators identified a class of metabolites called isoprenoids that are essential for the suppressive activity of activated Treg cells such as eTreg cells. Isoprenoids are required for cellular processes called posttranslational lipid modifications, specifically protein farnesylation and geranylgeranylation. These processes are mediated by Fntb and Pggt1b, respectively. Disruption of these processes by Treg cell-specific deletion of Fntb or Pggt1b causes mice to develop autoimmunity.

Further research into the metabolic signaling mechanisms revealed the discrete details of Treg cell-mediated immune suppression downstream of T cell receptor signaling. Fntb acts through two parallel pathways to promote eTreg cell persistence: the protein kinase mTORC1, which regulates metabolic reprogramming of Treg cells, and the immune receptor ICOS. Pggt1b enforces signaling through the small G protein Rac to support eTreg cell differentiation.

"We were able to dissect how metabolic regulation controls eTreg cell differentiation and maintenance," said first author and graduate student Wei Su of St. Jude Immunology. "This bidirectional interplay between intracellular signaling and metabolism allows eTreg cells to maintain the self-tolerance in our body."

"These pathways have been of long-standing interest outside of the immune system for a way to inhibit inflammatory responses," said study author Nicole Chapman, Ph.D., of St. Jude Immunology. "Our study provides a deeper understanding of the molecular interplay between signaling and metabolism and could allow for more potent and selective targeting of downstream metabolic functions in Treg cells."

Source:

Journal reference:

Su, W., et al. (2020) Protein Prenylation Drives Discrete Signaling Programs for the Differentiation and Maintenance of Effector Treg Cells. Cell Metabolism. doi.org/10.1016/j.cmet.2020.10.022.

Here is the original post:
Study reveals the metabolic signaling mechanisms that regulate function of eTreg cells - News-Medical.Net

Most Vaccines Can Be Give Safely, Even After Reactions – Medscape

For the majority of vaccine reactions, the vaccine can still be administered in graded doses, according to John Kelso, MD, from the UC San Diego School of Medicine.

John Kelso

"All anaphylactic reactions to vaccines should be evaluated in an attempt to determine the culprit allergen," but do not simply avoid giving the vaccine, he said during his presentation on the vaccine research frontlines at the American College of Allergy, Asthma & Immunology 2020 Annual Scientific Meeting.

It might be tempting to simply label the patient as "allergic to the vaccine," but that "may leave the patient inadequately immunized," he said.

It's best to investigate the allergy with available resources and following allergy investigation procedures, said Kelso.

If the patient has had a previous reaction to a vaccine and has a reaction immediately after receiving the vaccine, do a skin-prick test or an invitro lgE test of the vaccine and its components, Kelso recommended.

All ingredients in every vaccine are listed in the vaccine excipient summary appendix of the Pinkbook, which is published by the Centers for Disease Control and Prevention.

And an online compilation of excipients in vaccines per 0.5mL dose, from the John Hopkins Bloomberg School of Public Health, breaks down vaccines by component, and lists the excipients and allergens, alphabetically, including the amount per dose.

If the test is negative and additional doses of the vaccine are required, administer the vaccine as indicated. If the test is positive and additional doses of the vaccine are needed, they can be administered in graded doses.

The same procedure is recommended if a patient has a clinical history of allergy to gelatin, latex, or yeast, which are common ingredients in vaccines.

"Although there are possibilities of false positives, a 1to 100 dilution for the intradermal test has been shown to be nonirritating," Kelso reported. What's more, "it's important to note that there are no reports of patients who have had intradermal skin tests and have gone on to have a reaction."

If the patient has a reaction to the vaccine, but not immediately, usually no allergy workup needed. In almost all such cases, the vaccine can be administered, on the recommended schedule, in graded doses at 15minute intervals, under observation, he said. If a physician is reluctant to give additional doses, a lab test can be done to measure the patient's lgG antibodies to see if they are protected.

"Most influenza vaccines are literally grown in egg," Kelso said, and "they contain a residual amount of egg protein, or ovalbumin."

However, this has been thoroughly studied with injectable influenza vaccine and intranasal influenza vaccine, live and attenuated, and reactions are rare.

In 27 studies of inactivated vaccine administered to more than 4100 children, including those who have had anaphylactic reactions to egg, there were no reactions, he reported. And published reports describe 1129 children with egg allergy who received live attenuated intranasal flu vaccine, with no immediate systemic reactions.

"It turns out there's just not enough egg protein present to cause a reaction even in the most severely egg allergic patient," Kelso explained. The maximum amount of ovalbumin is less than 1g per 0.5mL dose of influenza vaccine, and amounts measured in independent laboratories are usually much lower than the amounts claimed.

"It is not necessary to inquire about egg allergy before the administration of any influenza vaccine, including on screening forms," according to the Recommendations for Prevention and Control of Influenza in Children, 20202021, issued recently by the American Academy of Pediatrics.

This is one of three main changes in vaccine administration that clinicians "may wish to make" in practice, Kelso said.

The second is that clinicians should be aware that Tdap, a vaccine for tetanus diphtheria and pertussis, can be given regardless of when a previous Tdvaccination was given. Limb swelling, which occurs in 2% to 3% of people after four or five doses, is not a contraindication to the vaccine, he explained.

And the third is that pregnant women can receive injectable (inactivated) influenza vaccine and Tdap, but not live vaccines.

Lisa Saiman

Social media focuses predominantly on negative experiences, which "are easier to perceive than the positive benefits of vaccination: the absence of disease," Lisa Saiman, MD, from the Columbia University Irving Medical Center in New York City, pointed out during her presentation.

The result is a cognitive bias against vaccination, "a disbelief of vaccine efficacy, and a mistrust in pharmaceutical companies and, of course, government," she said.

"But there is a spectrum of vaccine hesitancy and refusal," Saiman said. And there are several resources that physicians can use to explain the importance of vaccines to those who fall into the "cautious acceptor" and "fence sitter" categories, which will help providers maximize the number of patients they vaccinate.

Saiman recommends that providers use talking points from the Countering Vaccine Hesitancy clinical report to guide discussions with parents who are worried about vaccines.

Regular courses of immunization need to be followed, she emphasized. "During the COVID-19 pandemic, measles vaccination rates have declined," and we "clearly are at increased risk of future outbreaks."

"We need to provide catch-up vaccinations expeditiously, and pediatricians must communicate the effectiveness and safety of all vaccines," she stressed.

Kelso and Saiman have disclosed no relevant financial relationships.

American College of Allergy, Asthma & Immunology (ACAAI) 2020 Annual Scientific Meeting: Presented November3, 2020.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Follow this link:
Most Vaccines Can Be Give Safely, Even After Reactions - Medscape

AAAAI-Supported Food Allergy Bill Passes the House of Representatives – Benzinga

MILWAUKEE, Nov. 17, 2020 /PRNewswire-PRWeb/ -- The Food Allergy Safety, Treatment, Education, and Research (FASTER) Act (H.R. 2117), a bill supported by the AAAAI, passed the House of Representatives today with a unanimous voice vote. The FASTER Act directs the Centers for Disease Control and Prevention (CDC) to expand data collection of information related to food allergies and specific allergens, and revises the definition of major allergen to specifically include sesame. House Energy and Commerce Committee Chairman Frank Pallone (D-NJ), Ranking Member Greg Walden (R-OR), and Representative Doris Matsui (D-CA) spoke in support of the bill.

"The AAAAI joins with our Patient Advocacy Organization partners in celebrating the news that H.R. 2117 has successfully passed the House of Representatives," said AAAAI President Mary Beth Fasano, MD, MSPH, FAAAAI. "While it still needs to pass the Senate before it can be signed into law, this bill will do several things to improve the health and safety of Americans living with food allergies, including revising the definition of major allergens to include sesame, which is tremendously significant."

H.R. 2117 is sponsored by Representative Doris Matsui, who was joined by more than 90 bipartisan cosponsors. "Food allergies impact the daily lives of so many Americans, including our friends and family members," said Congresswoman Matsui. "Some of these food allergies can be serious and potentially be life-threatening diseases, and it's become abundantly clear to me that we need more research and evidence-based solutions to help understand, treat, and maybe one day prevent food allergies. I hope this legislation will provide progress treating allergies and improving the lives of those suffering from them."

The AAAAI continues to advocate for congressional adoption of H.R. 2117 which would advance recommendations from the National Academy of Medicine report "Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management, and Public Policy," including strengthening data collection on the prevalence of food allergies, and adding sesame to the list of allergens required to be listed on food labels, as well as providing flexibility for the Secretary of Health and Human Services to add any other food ingredients determined by regulation to be a major food allergen. The AAAAI joins its stakeholder partner FARE in support of this important legislation.

Passage of the FASTER Act comes after the Food and Drug Administration (FDA) recently issued a draft guidance titled "Voluntary Disclosure of Sesame as an Allergen". The document encourages food manufacturers to voluntarily declare sesame in the ingredient list on food labels. Comments on the draft guidance are due January 11, 2021. Additionally, the recently released Senate appropriations bill included a statement about allergen labeling expressing concern that the FDA has failed to take further action to require labeling for sesame and urging the agency to act swiftly to address this risk by requiring the same labeling for sesame as other major food allergens. Also included was report language requested by the AAAAI and other stakeholders which recognizes the prevalence of food allergy in the pediatric and adult communities, commends the ongoing work of the National Institute of Allergy and Infectious Diseases (NIAID) and the Consortium of Food Allergy Research (CoFAR), and encourages the NIAID to expand its clinical research network to add new centers of excellence in food allergy clinical care and to select such centers from those with a proven expertise in food allergy research.

AAAAI's professional governmental relations team and physician leadership continue to make a priority of encouraging federal research support for food allergies and related advocacy activities.

You can learn more about food allergies on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI's Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

###

Media Contact

April Presnell, The American Academy of Allergy, Asthma & Immunology, 414-272-6071, apresnell@aaaai.org

SOURCE The American Academy of Allergy, Asthma & Immunology

Go here to see the original:
AAAAI-Supported Food Allergy Bill Passes the House of Representatives - Benzinga

Analysis | Experts have doubts the first Covid-19 vaccines will bring herd immunity – News24

NEWS

Governments and officials are voicing hopes that Covid-19 coronavirus vaccines could bring herd immunity, with some calculating that immunising just two-thirds of a population could halt the pandemic and help protect whole communities or nations.

But the concept comes with caveats and big demands of what vaccines might be capable of preventing. Some experts say such expectations are misplaced.

For a start, figuring out whats needed to achieve herd immunity with Covid-19 vaccines involves a range of factors, several of which are unknown.

Read:Covid-19: No deal yet to access 90% effective vaccine tested in SA

What is the rate of the spread of the Covid-19-causing virus? Will the first vaccines deployed be able to stop transmission of the virus, or just stop people getting ill? How many people in a population will accept a vaccine? Will vaccines offer the same protection to everyone?

Herd immunity is sometimes wrongly understood as individual protection, said Josep Jansa, an expert in health emergency preparedness and response at the Stockholm-based European Centre for Disease Prevention and Control (ECDC).

Its inappropriate to think I will not be affected myself because there is herd immunity. Herd immunity refers to community protection, not to how an individual is protected.

The idea of herd community is to protect the vulnerable, said Eleanor Riley, a professor of immunology and infectious disease at the University of Edinburgh.

The ECDC uses an estimated herd immunity threshold of 67% for its models, while Chancellor Angela Merkel said this month that Covid-19 restrictions in Germany could be lifted if 60% to 70% of the population acquired immunity, either via a Covid-19 vaccine or through infection.

World Health Organisation experts have also pointed to a 65% to 70% vaccine coverage rate as a way to reach population immunity through vaccination.

The idea of herd community is to protect the vulnerable, said Eleanor Riley, a professor of immunology and infectious disease at the University of Edinburgh.

And the idea behind it is that if, say, 98% of a population have all been vaccinated, there will be so little virus in the community that the 2% will be protected. Thats the point of it.

REPRODUCTION RATE IS CRUCIAL

Central to the public health calculations on this concept for Covid-19 is the reproduction rate, or R value, of the virus that causes it.

This is a measure of how many other people an average infected person passes a pathogen on to in normal, or restriction-free, circumstances.

Assuming complete vaccine efficacy, herd immunity percentage thresholds for infectious diseases are calculated by dividing 1 by the R value, deducting the result from 1, and multiplying by 100.

Read:Herd immunity, second wave ... forget the jargon; this is what you need to know

For instance, herd immunity from highly contagious measles, with an estimated R value of 12 or higher, will kick in only if 92% or more within a group are immune. For a seasonal flu strain that could have an R value of 1.3, the threshold would be just 23%.

The problem is that for now we dont know exactly how fast the virus spreads without any precautions and with the normal travel and social activities we had a year ago, said Winfried Pickl, professor of immunology at the Medical University of Vienna.

With so many countries still operating in far from normal circumstances, the assumption should be that the Covid-19 R value would be closer to 4 than to 2, he said, since even with semi- or full lockdown measures the R value is around 1.5.

Additionally, anything less than 100% vaccine efficacy - such as the 90% or so suggested in early data on the Pfizer-BioNTech and Moderna Covid-19 shots - would require a matching rise in percentage of coverage to reach herd threshold.

Amesh Adalja, a scholar at the Johns Hopkins Center for Health Security, said a good target for immunity in the United States would be for more than 70% of the population to be inoculated, but added that the figure could go up if vaccines are less effective.

The idea of herd community is to protect the vulnerable,

Eleanor Riley, a professor of immunology and infectious disease at the University of Edinburgh

STOP TRANSMISSION IN THE HERD?

Experts say another important factor is whether the Covid-19 vaccines a government chooses to deploy can stop transmission of the virus.

Evidence so far suggests the first Covid-19 vaccines to come to market will at least stop people developing the disease. But it cannot be ruled out that people will still catch the Covid-19 coronavirus and pass it on to others unnoticed.

The idea of herd community is to protect the vulnerable, said Eleanor Riley, a professor of immunology and infectious disease at the University of Edinburgh. said Penny Ward, a visiting professor in pharmaceutical medicine at Kings College London.

Bodo Plachter, a professor and deputy director of the Institute of Virology at Germanys Mainz University teaching hospital, said that respiratory infections in particular can be hard to block completely with vaccines - although the shots will go some way to reducing the amount of circulating virus.

It may well be that vaccinated people will shed fewer viruses, he said. But it would be a mistake to assume vaccination alone can suppress a pandemic.

Read:The party of Luthuli is imploding

FOCUS ON PROTECTING THE VULNERABLE?

Edinburghs Riley said this suggests that for now, pursuing an idea of herd immunity through Covid-19 vaccination is fruitless.

A better approach, she said, could be to turn herd immunity on its head, and use the first limited supplies of vaccines to protect those most in need, without worrying about the more robust members of the herd who can live relatively happily with the virus.

Lets forget about protecting the masses to protect the vulnerable, she said. Lets directly protect the vulnerable. Reuters

news you need

Continued here:
Analysis | Experts have doubts the first Covid-19 vaccines will bring herd immunity - News24

Analysis: Can first COVID-19 vaccines bring herd immunity? Experts have doubts – Reuters

FRANKFURT/LONDON (Reuters) - Governments and officials are voicing hopes that COVID-19 vaccines could bring herd immunity, with some calculating that immunising just two-thirds of a population could halt the pandemic disease and help protect whole communities or nations.

But the concept comes with caveats and big demands of what vaccines might be capable of preventing. Some experts say such expectations are misplaced.

For a start, figuring out whats needed to achieve herd immunity with COVID-19 vaccines involves a range of factors, several of which are unknown.

What is the rate of the spread of the COVID-19-causing virus? Will the first vaccines deployed be able to stop transmission of the virus, or just stop people getting ill? How many people in a population will accept a vaccine? Will vaccines offer the same protection to everyone?

Herd immunity is sometimes wrongly understood as individual protection, said Josep Jansa, an expert in health emergency preparedness and response at the Stockholm-based European Centre for Disease Prevention and Control (ECDC).

Its inappropriate to think I will not be affected myself because there is herd immunity. Herd immunity refers to community protection, not to how an individual is protected.

The ECDC uses an estimated herd immunity threshold of 67% for its models, while Chancellor Angela Merkel said this month that COVID-19 restrictions in Germany could be lifted if 60% to 70% of the population acquired immunity, either via a COVID-19 vaccine or through infection.

World Health Organization experts have also pointed to a 65%-70% vaccine coverage rate as a way to reach population immunity through vaccination.

The idea of herd community is to protect the vulnerable, said Eleanor Riley, a professor of immunology and infectious disease at the University of Edinburgh. And the idea behind it is that if, say, 98% of a population have all been vaccinated, there will be so little virus in the community that the 2% will be protected. Thats the point of it.

Central to the public health calculations on this concept for COVID-19 is the reproduction rate, or R value, of the virus that causes it. This is a measure of how many other people an average infected person passes a pathogen on to in normal, or restriction-free, circumstances.

Assuming complete vaccine efficacy, herd immunity percentage thresholds for infectious diseases are calculated by dividing 1 by the R value, deducting the result from 1, and multiplying by 100.

For instance, herd immunity from highly contagious measles, with an estimated R value of 12 or higher, will kick in only if 92% or more within a group are immune. For a seasonal flu strain that could have an R value of 1.3, the threshold would be just 23%.

The problem is that for now we dont know exactly how fast the virus spreads without any precautions and with the normal travel and social activities we had a year ago, said Winfried Pickl, professor of immunology at the Medical University of Vienna.

With so many countries still operating in far from normal circumstances, the assumption should be that the COVID-19 R value would be closer to 4 than to 2, he said, since even with semi- or full lockdown measures the R value is around 1.5.

Additionally, anything less than 100% vaccine efficacy - such as the 90% or so suggested in early data on the Pfizer-BioNTech and Moderna COVID-19 shots - would require a matching rise in percentage of coverage to reach herd threshold.

Amesh Adalja, a scholar at the Johns Hopkins Center for Health Security, said a good target for immunity in the United States would be for more than 70% of the population to be inoculated, but added that the figure could go up if vaccines are less effective.

STOP TRANSMISSION IN THE HERD?

Experts say another important factor is whether the COVID-19 vaccines a government chooses to deploy can stop transmission of the virus.

Evidence so far suggests the first COVID-19 vaccines to come to market will at least stop people developing the disease. But it cannot be ruled out that people will still catch the SARS-CoV-2 virus and pass it on to others unnoticed.

While protection against illness has a value for an individual, it will not prevent circulation of virus and risk of disease in unvaccinated (people), said Penny Ward, a visiting professor in pharmaceutical medicine at Kings College London.

Bodo Plachter, a professor and deputy director of the Institute of Virology at Germanys Mainz University teaching hospital, said that respiratory infections in particular can be hard to block completely with vaccines - although the shots will go some way to reducing the amount of circulating virus.

It may well be that vaccinated people will shed fewer viruses, he said. But it would be a mistake to assume vaccination alone can suppress a pandemic.

Edinburghs Riley said this suggests that for now, pursuing an idea of herd immunity through COVID-19 vaccination is fruitless.

A better approach, she said, could be to turn herd immunity on its head, and use the first limited supplies of vaccines to protect those most in need, without worrying about the more robust members of the herd who can live relatively happily with the virus.

Lets forget about protecting the masses to protect the vulnerable, she said. Lets directly protect the vulnerable.

Reporting by Kate Kelland in London and Ludwig Burger in Frankfurt, Additional reporting by Carl ODonnell in New York, Editing by Timothy Heritage

See more here:
Analysis: Can first COVID-19 vaccines bring herd immunity? Experts have doubts - Reuters

Griffith and Nanostring launch Centre of Excellence in spatial biology – Griffith News

Griffith University will establish a Centre of Excellence (CoE) in spatial biology in collaboration with Nanostring Technologies, a publicly held provider of life science tools for translational research and molecular diagnostic products.

Dr Nicholas West, from the Mucosal Immunology Research Group at Griffith Universitys Menzies Health Institute Queensland, said the CoE was the first of its type in Australia and would provide the scientific community in the Asia Pacific region with the latest in innovative immune profiling techniques.

The Griffith University Centre of Excellence in Spatial Biology will transform our capability to undertake innovative and state-of-the-art immunophenotyping across a number of diseases, he said.

The Griffith University Centre of Excellence in Spatial Biology will transform our capability to undertake innovative and state-of-the-art immunophenotyping across a number of diseases

With a focus on mucosal and tissue immunology, we will be able to provide innovative research in oncology, atopic and chronic inflammatory diseases and in data science and bioinformatics.

For instance, this offers the potential for great advances in treatment of people with cancer, where tailoring treatment requires an understanding of the tumour biology, that is, the cells driving cancer growth.

Nanostring recently launched the GeoMx Digital Spatial Profiler (DSP). Dr West said spatial biology was the next frontier.

Spatial biology allows for the comprehensive assessment and characterisation of immune cells and molecules within their morphological context.

Our ability to understand which patients will respond to different treatments has been limited by our ability to characterise the cells and molecules within the tissue environment.

GeoMx Spatial Profiling allows us to assess the cells and molecules in the tumour for a targeted understanding of the biology of the disease.

Recently this has led to new trials to determine whether key immune cells are predictive of response to immunotherapy in patients with melanoma.

This cutting-edge technology allows measuring and mapping of the spatial distribution of proteins and RNA in a tissue sample, where existing methods, which rely on the extraction of RNA or isolation of cells, have resulted in the loss of spatial information in diseased tissue.

It allows us to gain insight into the causes of disease, progression, treatment and resolution.

Deputy Vice Chancellor Research, Professor Mario Pinto said Griffith researchers were highly regarded as being at the forefront of discovery.

As a research-intensive institution, Griffith is investigating and opening doors to discovery and innovations which can help improve peoples lives.

Having access to cutting edge technology ensures a front row seat to the future.

Having access to cutting edge technology ensures a front row seat to the future

Since 2018, the University, through its leading health and medical research institute, the Menzies Health Institute Queensland, has partnered with NanoString to provide researchers and clinicians, along with their commercial partners, the capability and expertise to undertake state-of-the-art genomics, immunology and data science.

The CoE is shaping up to be the core facility of choice for this technology in the wider Asian region so there is a lot of interest in our emerging capabilities.

Given Australia and our local environment is now almost COVID free, we are able to undertake all types of basic and clinical research.

Dr West said the GeoMx Digital Spatial Profiler (DSP) enabled high throughput multiplex spatial profiling of both RNA and protein targets in a variety of sample types, including FFPE tissue sections for researcher both in translational science and clinical settings.

Since 2019, there have been more than 28 peer-reviewed research articles using GeoMx DSP published in high impact journals including Nature, Cell and Nature Medicine.

Access to this technology is considered essential for researchers in the field of immune-oncology, neuroscience and developmental biology where spatial information is key to the next breakthrough.

This partnership means we will be able to bring the latest NanoString research and development opportunities to research in the Australian community, offering efficient, comprehensive and tailored services to generate high impact research data, Dr West said.

The Centre of Excellence at Griffith University will serve as a portal for researchers across Asia Pacific to undertake research and development activities.

It will also offer a stage for researchers in the spatial biology community to develop multi-centre collaborations to drive the next transformation in translational science.

For further information on access to the GeoMx Spatial Profiling technology visit http://www.griffith.edu.au/griffith-health/systems-biology-data-science or email Dr West at [emailprotected]

View post:
Griffith and Nanostring launch Centre of Excellence in spatial biology - Griffith News

A Toronto doctor says covered patios aren’t much safer than being inside – blogTO

As thepandemic continues, many restaurants have turned to covered and heated outdoor patios to maintain business. However, an expert is now saying that this isn't much safer than being indoors.

University of Toronto doctor and professor in the immunology departmentEleanor Fish told HuffPost Canadathat patios with makeshift tents defeatthe purpose of actuallybeing outside.

"Outdoors is meant to be outdoors," Fish said, adding that patios worked in the summer when people could social distance and air could flow freely.

"As soon as you start enclosing space, you can fool yourself that it's still outdoors, but the reality is that unless you have air circulating to the outside very efficiently, people are putting themselves at risk."

As we know, good ventilation and airflow can help reduce the spread of COVID-19as airborne transmission is possible.

However, Fish went on to say that "as soon as you start putting walls up, you're creating an indoor space" and "you're circulating [the virus] indoors without venting it."

Many restaurants and bars across the country and across Toronto have revamped their patios with heat lamps and tented or transparent walls.

In fact, Toronto's biggest heated and covered patio yet, called The Marquee at Cabana's waterfront, opened last month. Antler, a restaurant known for its game meats, also opened a tented and heated patio called Antler Hunt Camp just over a week ago.

While Fishsaidshe understands that people miss their friends and want a social connection, she added that this is not the way to move forward.

"I think it's really risky behaviour for people to be out and about."

Instead, she suggests supporting the restaurant industry by ordering food for delivery or arranging curbside pickup.

"We shouldn't be going to any sort of outdoor patio at this stage of the game."

Go here to see the original:
A Toronto doctor says covered patios aren't much safer than being inside - blogTO

Marketing Psychology: 10 Revealing Principles of Human …

One key part of being a great marketer is understanding how (and why)people think and act the way they do. It's much harder tocreate compelling content marketing, for example,if you dont know why it would be compelling to your audience in the first place.

Before you jumpinto the tactical nitty-gritty of marketing, its really helpful to understand how people operate which is essentially what the entire field of psychology attempts to explain. Understanding some key principles of psychology can take your marketingfrom good to amazing, all because the right audience is reading and identifying with it (and most likelyconverting on it, too).

To help you attract, convince, and convert more people with your marketing, you should know the following lessons about psychology.

Have you ever played the game where one person says a word, and the other immediately responds with the first thingthat comes to mind?

That'skind of how priming works. You're exposed to one stimulus, and it affects how you respond to another stimulus.Psychology Todaygives the example of two groups ofpeople reading the word "yellow" followed by either "sky" or "banana."Because people have a semantic association between the fruit and its color, the "yellow-banana" group will recognize the word "banana" fasterthan the "yellow-sky" group recognizes "sky."

What's this got to do with marketing? Lots.Using subtle priming techniques, you could help your website visitors remember key information about your brand -- and maybe even influence their buying behavior.

It's been testedbefore. Ina study by Naomi Mandel and Eric J. Johnson, researchers manipulated the background design of a website to see if it'd affect consumers' product choices. Participants were asked to choose between two products in one category (like a Toyota vs. a Lexus).According to Psychology Today, "they found that visitors who had been primed on money (the websites background was green with pennies on it) looked at price information longer than those who had been primed on safety. Similarly, consumers who had been primed on comfort looked at comfort information longer than those primed on money."

Source: Journal of Consumer Research

So if you're trying to make use of priming in your marketing, think about the small details. They could be the difference between someone buying your highest product price point and bouncing from your page.

Introduced in Dr. Robert Cialdinis book, Influence: The Psychology of Persuasion, the concept of reciprocity is simple -- if someone does something for you, you naturally will want to do something for them.

If you've ever gotten a mint with your billat a restaurant, you've been the victim of reciprocity. According to Cialdini, when servers bring a check to their patrons without a mint,the diners will tip according to their perceptions of the service given. With one mint,the tip jumps up 3.3%. Two mints? The tipjumps "through the roof" to roughly20%.

In your marketing,there are a lot of ways to take advantage of reciprocity. You dont have to be rolling in dough to give something away; it can be anything from a branded sweatshirt, to an exclusive ebook, to a free desktop background, to your expertise on a difficult subject matter. Even something as simple as a hand-written note can go a long way in establishing reciprocity. Just be sure you're giving away the free thingbeforeyou ask for something in return.

Most marketers are aware of this concept already, but it was too important to leave out from this list. If you're not familiar with it, social proofis the theory that people will adopt thebeliefs or actions of a group of people theylike or trust. In other words, its the me too effect. Think of this like an awkward middle school dance -- few people want to be the first one on the dance floor, but once a few people are there, everyone else wants to join in. (Keep in mind, this desire to conform doesnt go away when you get older and less bashful about your dance moves.)

One easy way to make the most of social proof is on your blog. If you're not already, use social sharing and follow buttons that display the number of followers your accounts have or the number of shares a piece of content has. If those numbers are front and center and you already have a few people sharing your post, people who stumble on your post later will be much more likely to share.

You'll often see this effect in pricing models -- one price point is intentionally includedto entice you to choose the most expensive option.

In Dan Airley's famous TED talk,"Are we in control of our own decisions?", he describes an ad fromThe Economist outlining their latest subscription packages. Here's what they offered:

Crazy, right? You could get the print only subscription and the online and print subscription for the same price. Why would they offer that?

That's what Airley thought, too. He reached out to the folks at The Economist, but he never got a straight answer from them.

So he decided to run his own study with 100 MIT students. He gave them the pricing packages outlined above and asked which onethey'd want to buy. When all three options were there, studentschose the combo subscription -- it was the best deal, right? But when he removed the "useless" option (the print subscription for $125), the students preferred the cheapest option.

Turns out that middle option wasn't that useless after all -- it gave students a frame of reference for how "good" the combo deal was and enticed them to pay more for that deal.

So if you're looking to increase conversions on a landing page with two options, you might want to add a third. It could help increase the conversion rate of the option you'd ultimately want people to take.

Ever gone to buy airline tickets and seen a tagline that says Only 3 seats left at this price! Yup, thats scarcity (another Cialdini concept). This psychology principle goes back to the simple formula of supply and demand: The more rare the opportunity, content, or product is, the more valuable it is.

In 1975,Worchel, Lee, and Adewole conducted a study to see how scarcity affected people's perception. At the start of the study, theyasked people to rate chocolate chip cookies. According to an article by my colleague Lanya Olmsteadthat describes the experiment, "[The researchers] put 10cookies in one jar, and two of the same cookies in another jar. The cookies from the two-cookie jar received ratingstwiceas high as the 10 cookie jar even though the cookies were exactly the same."

But if you want to properly use this principle, you need to be careful how you word it. If you approach the scarcity concept as if there used to be a ton of a product or service, but due to popular demand theres a few left, people will be very receptive. On the other hand, if you approach it from the angle that there are only a few products total, so get it now, the principle wont be as effective. Check out this post from Nir and Far for a deeper explanation on why that distinction is important.

Ever wondered why it's so hard to resist a sale at your favorite clothing store?

Often, it has to do with anchoring -- peoplebase decisions onthe first piece of information theyreceive. So if my favorite store typically retails jeans for $50, but I find them on sale for $35, I'll be ecstatic. "I just got a crazy deal on these jeans,"I'll think. I'll probably even buy them. But if my friend typically shops for jeans that are $20, she won't be nearly as impressed.

For marketers, anchoring is important to know -- especially if you're ever running a sale.You'll want to clearly state the initial price of the product (this is "setting" the anchor), and thendisplay the sale price right next to it. You might even explain how much of a percentage off your customers will receive with the sale.

Image credit: Express

Ever heard about a product and then start seeing it everywhere you look?You can thank theTheBaader-Meinhof Phenomenon.It starts happening after you encounter something for the first time, and then you start noticingit cropping up in everyday life. Suddenly you see ads for the product every time you watch TV. And when you go to the grocery store, you happen to walk down the aisle and spot it. And alllllll of your friends all have the product.

It's weird right? Here'swhy you're suddenly seeing this new thing everywhere.

According to PS Mag,this phenomenon (also called "the frequency illusion") is caused by two processes. "The first, selective attention, kicks in when youre struck by a new word, thing, or idea; after that, you unconsciously keep an eye out for it, and as a result find it surprisingly often. The second process, confirmation bias, reassures you that each sighting is further proof of your impression that the thing has gained overnight omnipresence."

For marketers, this phenomenon is precisely whynurturing is incredibly important. Once someone starts noticing your brand (aka clicking around on your website), you'll want to help them start seeing you "everywhere." Send them targetednurturing emails and retargeting ads based on their behavior, and you could increase thepossibility of them converting.

According toa study byPoppenk, Joanisse, Danckert, and Khler, people are more likely to rememberthe gist of what someone said, not the specific details. So when you attend a session on how to blog for your business, you're most likely going to remember details like "Have another person edit your work," not "Send a Google Doc three business days ahead of time to a peer so they can edit your work. Don't forget to use Track Changes so you know what you missed!"

They called this the "verbatim effect." And itcan have a huge effect on how your content performs.

To begin with, people are spending less and less time actually reading online. According to data from Chartbeat, more than half of your visitors will spend less than 15 seconds on your site. So if people aren't reading your contentandnot likely to remember specific details, what's a marketer to do?

I'd recommend spending even more time than you already are on perfecting your headline. Not only should it be search- and sharing-friendly, but it should also accurately describe what's in your article. This way, when people are looking for more information on a given topic, they'll think of that one helpful article they read a while ago and Googlethe topic to find it again. If you've done the work, you should appear in the search results.If you need some help writing compelling headline copy, check out this post on our blog.

People have a limited amount of space in their short-term memory. In fact, most people can only remember seven pieces of information (plus or minus two pieces in any given situation) at a time.

To cope, most people tend to cluster similar pieces of information together. For example, if you had a whole grocery list of random items, most people would tend to mentally group items into certain categories (dairy, grain, meat, etc.) to be able to better remember what exactly was on the list.

So when you're creating content, keep clustering in mind. How can you design and lay out your content to increase memory retention? One way to do it is by grouping similar topics together --either under numbered bullet points or with different header sizes. Besides being much easier to scan, your writing will be much easier to remember and recall down the road -- especially if youre creating long lists of content.

Loss aversion means pretty much exactly what it sounds like: Once someone has something, they realllllly don't like to lose it.

WhenDaniel Kahneman studied this concept, participants were given mugs, chocolate, or nothing. Then, they were asked to make a choice, they were give two options: If they were given an object, they could trade their objects, or if they were given nothing, they could choose one of the two items. The result? Roughly half of the participants who started with no items chose mugs, but 86% of those given mugs to begin with stuck with that item.

Moral of the story? People don't like to lose what they've already gained.

Though this could open up some semi-sketchy doors for certain types of marketers, loss aversion couldhave a significant factor in freemium products and increasedproduct adoption. For example, you couldungate a feature for the free version of your product for a certain amount of time. After that time period is up, that feature could be removed unless you upgrade to becoming a paying customer. While you certainly have to be careful how you play to this psychological need, loss aversion is a very important concept for every marketer to know.

What other psychology studies and concepts do you swear by? Share your favorites in the comments.

Editor's Note: This post was originally published in July 2013and has been updated for freshness, accuracy, and comprehensiveness.

Excerpt from:
Marketing Psychology: 10 Revealing Principles of Human ...